Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:HALO
Previous Symbol
CUSIP40637H10
Phone858-794-8889
Debt
Debt-to-Equity Ratio0.24
Current Ratio3.09
Quick Ratio2.96
Price-To-Earnings
Trailing P/E Ratio32.13
Forward P/E Ratio-25.82
P/E GrowthN/A
Sales & Book Value
Annual Sales$316.61 million
Price / Sales6.60
Cash Flow$0.4390 per share
Price / Cash Flow32.94
Book Value$1.46 per share
Price / Book9.90
Profitability
EPS (Most Recent Fiscal Year)$0.45
Net Income$62.97 million
Net Margins16.24%
Return on Equity18.87%
Return on Assets9.44%
Miscellaneous
Employees255
Outstanding Shares144,560,000
Market Cap$2.17 billion
OptionableOptionable
Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings data on Tuesday, November, 6th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.04. The biopharmaceutical company had revenue of $25.60 million for the quarter, compared to the consensus estimate of $30.42 million. Halozyme Therapeutics had a net margin of 16.24% and a return on equity of 18.87%. The company's quarterly revenue was down 59.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.02 EPS. View Halozyme Therapeutics' Earnings History.
When is Halozyme Therapeutics' next earnings date?
What guidance has Halozyme Therapeutics issued on next quarter's earnings?
Halozyme Therapeutics issued an update on its FY 2018 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $150-160 million, compared to the consensus revenue estimate of $126.97 million.
What price target have analysts set for HALO?
8 analysts have issued 1-year price targets for Halozyme Therapeutics' shares. Their forecasts range from $17.00 to $27.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 45.2% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.
What is the consensus analysts' recommendation for Halozyme Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Halozyme Therapeutics.
What are Wall Street analysts saying about Halozyme Therapeutics stock?
Here are some recent quotes from research analysts about Halozyme Therapeutics stock:
- 1. According to Zacks Investment Research, "Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine. " (12/19/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-month price target of $27/share of Halozyme. We recently hosted investors for a meeting with HALO management on our Post ASH-Thrash Bus Tour. Interest remains high in the core ENHANZE business and potential new partners, but also expansion of clinical-stage development candidates with current partners. Recall that the agreements with current partners include multiple candidates for which only a fraction have entered the clinic. Companies have started to understand the potential benefits of ENHANZE, such as the ability to take daratumumab, which currently requires a 4-6 hour IV infusion, down to a 3-5 minute injection." (12/5/2018)
Has Halozyme Therapeutics been receiving favorable news coverage?
Media coverage about HALO stock has been trending neutral this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Halozyme Therapeutics earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP) and Regenxbio (RGNX).
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Dr. Helen I. Torley, Pres, CEO & Director (Age 55)
- Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 50)
- Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 61)
- Mr. Mark J. Gergen, Former Chief Operating Officer (Age 55)
- Mr. Ed Gemo, VP, Chief Information & Security Officer
Who are Halozyme Therapeutics' major shareholders?
Halozyme Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Third Security LLC (9.75%), Vanguard Group Inc. (9.21%), Vanguard Group Inc (9.21%), BlackRock Inc. (8.23%), Iridian Asset Management LLC CT (6.40%) and JPMorgan Chase & Co. (2.49%). View Institutional Ownership Trends for Halozyme Therapeutics.
Which major investors are selling Halozyme Therapeutics stock?
HALO stock was sold by a variety of institutional investors in the last quarter, including Third Security LLC, Baker BROS. Advisors LP, Prudential Financial Inc., BlackRock Inc., Morgan Stanley, Renaissance Technologies LLC, First Trust Advisors LP and FMR LLC. View Insider Buying and Selling for Halozyme Therapeutics.
Which major investors are buying Halozyme Therapeutics stock?
HALO stock was acquired by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Iridian Asset Management LLC CT, Thrivent Financial for Lutherans, Pictet Asset Management Ltd., Vanguard Group Inc, Vanguard Group Inc., Elk Creek Partners LLC and Man Group plc. View Insider Buying and Selling for Halozyme Therapeutics.
How do I buy shares of Halozyme Therapeutics?
Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
One share of HALO stock can currently be purchased for approximately $14.46.
How big of a company is Halozyme Therapeutics?
Halozyme Therapeutics has a market capitalization of $2.17 billion and generates $316.61 million in revenue each year. The biopharmaceutical company earns $62.97 million in net income (profit) each year or $0.45 on an earnings per share basis. Halozyme Therapeutics employs 255 workers across the globe.
What is Halozyme Therapeutics' official website?
How can I contact Halozyme Therapeutics?
Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]
MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.
